Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl NP7
New Haven, CT 06511
- Smilow Cancer Hospital at Yale New Haven35 Park Street, Fl NP7New Haven, CT 06511
Maximilian Stahl, MD
Leukemia & Lymphoma, Hematology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Board Certified in
Internal Medicine, Hematology (Internal Medicine)
, and Medical Oncology
Titles
- Assistant Professor
- Director Leukemia and Myeloid Malignancy Program, Yale Cancer Center
- Chief Duffy Hematology Firm, Yale-New Haven Hospital
Education & Training
- Research FellowThe Rockefeller University (2021)
- Clinical FellowMemorial-Sloan Kettering Cancer Center (2021)
- Chief ResidentYale School of Medicine (2018)
- ResidentYale School of Medicine (2017)
- InternYale School of Medicine (2015)
- Post-doctoral FellowYale University (2014)
- MDHannover Medical School (2013)
Languages Spoken
- English
- Deutsch (German)
Additional Information
Honors & Recognitions
- Translational Research Program Award: Leukemia and Lymphoma Society (2023)
- Abstract achievement award : American Society of Hematology (2020)
- Abstract achievement award : American Society of Hematology (2017)
- Stephen R. Shell Award: Yale University (2017)
- HONORS award: American Society of Hematology (2017)
- Abstract achievement award : American Society of Hematology (2016)
- Samuel D. Kuslan Award : Yale University (2016)
- Full Academic Scholarship: German National Academic Scholarship Foundation (Studienstiftung des Deutschen Volkes) (2006)
Board Certifications
- AB of Internal Medicine, Hematology (Internal Medicine) (2021)
- AB of Internal Medicine, Medical Oncology (2021)
- AB of Internal Medicine, Internal Medicine (2017)
Publications
- Bidikian A, Bewersdorf J, Kewan T, Podoltsev N, Stahl M, Zeidan A. Imetelstat in myeloid malignancies: current data and future directions. Expert Review Of Anticancer Therapy 2025, ahead-of-print: 1-12. PMID: 40116730, DOI: 10.1080/14737140.2025.2482721.
- Alhajahjeh A, Stahl M, Kim T, Kewan T, Stempel J, Zeidan A, Bewersdorf J. Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment. Expert Review Of Anticancer Therapy 2025, ahead-of-print: 1-22. PMID: 40122075, DOI: 10.1080/14737140.2025.2483855.
- Petit C, Higue J, Acheaibi Z, Gilhodes J, Hospital M, Devillier R, Bewersdorf J, Goldberg A, Pigneux A, Vey N, Récher C, Stahl M, Bertoli S, Dumas P, Garciaz S. Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC‐DATAML‐MSKCC Retrospective Study. American Journal Of Hematology 2025, 100: 906-908. PMID: 40088036, DOI: 10.1002/ajh.27626.
- Shimony S, Stahl M, Stone R. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management. American Journal Of Hematology 2025, 100: 860-891. PMID: 39936576, PMCID: PMC11966364, DOI: 10.1002/ajh.27625.
- Luskin M, Murakami M, Keating J, Flamand Y, Winer E, Garcia J, Stahl M, Stone R, Wadleigh M, Jaeckle S, Hagopian E, Weinstock D, Liegel J, McMasters M, Wang E, Stock W, DeAngelo D. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia. Blood 2025, 145: 577-589. PMID: 39374521, DOI: 10.1182/blood.2024025800.
- How J, Leiva O, Redd R, Marneth A, DeAngelo D, Dieli-Conwright C, El-Jawahri A, Kamaz B, Kim C, Lindsley C, Luskin M, Stahl M, Wazir M, Weeks L, Hobbs G. Cardiovascular Risk Factors in Myeloproliferative Neoplasms: Associations with Survival and Thrombotic Outcomes. Blood Vessels Thrombosis & Hemostasis 2025, 100051. DOI: 10.1016/j.bvth.2025.100051.
- Bidikian A, Bewersdorf J, Kewan T, Stahl M, Zeidan A. Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them. Cancers 2024, 16: 4092. PMID: 39682277, PMCID: PMC11640703, DOI: 10.3390/cancers16234092.
- Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, 66: 488-496. PMID: 39560957, DOI: 10.1080/10428194.2024.2426073.
- A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDSNorman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, Stahl M, Eighmy W, Zeidan A. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Review Of Hematology 2024, 17: 755-767. PMID: 39474840, DOI: 10.1080/17474086.2024.2422554.
- Bewersdorf J, Hasle V, Shallis R, Thompson E, De Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab. Blood 2024, 144: 4585. DOI: 10.1182/blood-2024-194929.
- Chen E, Liu Y, Bell H, Galinsky I, Luskin M, Winer E, Stahl M, Vedula R, Volpe V, DeAngelo D, Quillen K, Ryan J, Minihane E, Hersch M, Leonard R, Neuberg D, Stone R, Letai A, Lane A, Garcia J. Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study. Blood 2024, 144: 4580-4580. DOI: 10.1182/blood-2024-198284.
- Zhang J, Shimony S, Liu Y, Inyang E, Chen E, Aguirre L, Bystrom R, Rolles B, Stone R, DeAngelo D, Tiao E, Stahl M. Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy. Blood 2024, 144: 5175-5175. DOI: 10.1182/blood-2024-200358.
- Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Goshua G, Bewersdorf J. Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia. Blood 2024, 144: 788. DOI: 10.1182/blood-2024-201535.
- Aguirre L, Bewersdorf J, Liu Y, Shallis R, Boussi L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Ling K, Chen E, Wadleigh M, Stein E, Goldberg A, Zeidan A, Shimony S, Stahl M. Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics. Blood 2024, 144: 4267-4267. DOI: 10.1182/blood-2024-202744.
- Shimony S, Wang Y, Cronin A, Walsh T, Charles A, Slopen N, Stahl M, Bystrom R, Luskin M, Abel G, DeAngelo D, Stone R, Lindsley R, Hantel A. Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group. Blood 2024, 144: 5171-5171. DOI: 10.1182/blood-2024-203644.
- Stone R, DeAngelo D, Letai A, Galinsky I, Weiner H, Halpin A, Noyes L, Smith H, Lombardi C, Leonard R, Fell G, Flammand Y, Ryan J, Konopleva M, Wadleigh M, Stahl M, Chen E, Volpe V, Winer E, Garcia J, Luskin M, Patel A. Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia. Blood 2024, 144: 4261. DOI: 10.1182/blood-2024-203683.
- Potnis K, Ito S, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States. Blood 2024, 144: 3644. DOI: 10.1182/blood-2024-204312.
- Boussi L, Bewersdorf J, Liu Y, Shallis R, Aguirre L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Ling K, Zeidan A, Goldberg A, Stein E, Shimony S, Stahl M. Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities. Blood 2024, 144: 4281-4281. DOI: 10.1182/blood-2024-204467.
- Bystrom R, Bewersdorf J, Liu Y, Schaefer E, Shallis R, Boussi L, Zucenka A, Garciaz S, Aguirre L, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Ling K, Stein E, Goldberg A, Zeidan A, Shimony S, Stahl M. The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study. Blood 2024, 144: 2947-2947. DOI: 10.1182/blood-2024-205581.
- Iat A, Bewersdorf J, Gilhodes J, Liu Y, Shallis R, Boussi L, Zucenka A, Bystrom R, DeAngelo D, Berton G, Soua A, Ling K, Aguirre L, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Goldberg A, Zeidan A, Cluzeau T, Shimony S, Stahl M, Garciaz S. Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia. Blood 2024, 144: 1508. DOI: 10.1182/blood-2024-207045.
- Chin K, Derkach A, Famulare C, Gupta G, Borge P, Geyer M, Goldberg A, Haque T, Park J, Roeker L, Tallman M, Stahl M, Stein E. HMA/Ven Treatment Modifications and Associated Outcomes in IDH -Mutant AML. Blood 2024, 144: 5962-5962. DOI: 10.1182/blood-2024-211733.
- Alhajahjeh A, Rotter L, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database. JCO Global Oncology 2024, 10: e2400316. PMID: 39621951, DOI: 10.1200/go-24-00316.
- Rotter L, Alhajahjeh A, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Analyzing determinants of premature trial discontinuation in leukemia clinical trials. Leukemia & Lymphoma 2024, 66: 289-297. PMID: 39440622, DOI: 10.1080/10428194.2024.2416565.
- Bidikian A, Bewersdorf J, Shallis R, Getz T, Stempel J, Kewan T, Stahl M, Zeidan A. Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions. Expert Review Of Anticancer Therapy 2024, 24: 1131-1146. PMID: 39367718, DOI: 10.1080/14737140.2024.2414071.
- Chin K, Derkach A, Famulare C, Gupta G, Borge P, Geyer M, Goldberg A, Haque T, Park J, Roeker L, Tallman M, Stahl M, Stein E. HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML. Leukemia & Lymphoma 2024, 66: 270-278. PMID: 39397429, DOI: 10.1080/10428194.2024.2411436.
- Venkat R, Redd R, Harris A, Aryee M, Marneth A, Kamaz B, Kim C, Wazir M, Weeks L, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hobbs G, How J. Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis. Blood Advances 2024, 8: 6043-6054. PMID: 39293089, PMCID: PMC11635702, DOI: 10.1182/bloodadvances.2024013777.
- Bewersdorf J, Shimony S, Shallis R, Liu Y, Berton G, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Bystrom R, Lindsley R, Chen E, Perez J, Stein A, Pullarkat V, Aldoss I, DeAngelo D, Neuberg D, Stone R, Garciaz S, Ball B, Stahl M. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML. Blood Advances 2024, 8: 4845-4855. PMID: 38941537, PMCID: PMC11416634, DOI: 10.1182/bloodadvances.2024012858.
- Getz T, Bewersdorf J, Kewan T, Stempel J, Bidikian A, Shallis R, Stahl M, Zeidan A. Beyond HMAs: Novel Targets and Therapeutic Approaches. Seminars In Hematology 2024, 61: 358-369. PMID: 39389839, DOI: 10.1053/j.seminhematol.2024.08.001.
- Jann J, Hergott C, Winkler M, Liu Y, Braun B, Charles A, Copson K, Barua S, Meggendorfer M, Nadarajah N, Shimony S, Winer E, Wadleigh M, Stone R, DeAngelo D, Garcia J, Haferlach T, Lindsley R, Luskin M, Stahl M, Tothova Z. Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia 2024, 38: 1992-2002. PMID: 39033241, PMCID: PMC11347381, DOI: 10.1038/s41375-024-02347-y.
- Alhajahjeh A, Bewersdorf J, Bystrom R, Zeidan A, Shimony S, Stahl M. Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome. Leukemia & Lymphoma 2024, 65: 1541-1551. PMID: 38962996, DOI: 10.1080/10428194.2024.2367040.
- Santini V, Stahl M, Sallman D. TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates. American Society Of Clinical Oncology Educational Book 2024, 44: e432650. PMID: 38768424, DOI: 10.1200/edbk_432650.
- Badar T, Nanaa A, Atallah E, Shallis R, Craver E, Li Z, Goldberg A, Saliba A, Patel A, Bewersdorf J, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy S, Zeidan A, Kota V, Patnaik M, Litzow M. Prognostic impact of ‘multi-hit’ versus ‘single-hit’ TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. Haematologica 2024, 109: 3533-3542. PMID: 38813716, PMCID: PMC11532685, DOI: 10.3324/haematol.2024.285000.
- Khawaja M, Naqash A, Schneider R, Shastri A, Stahl M, Moser J, Abdel Karim N, Madanat Y, Jonas B, Stein E, Gadgeel S, McCloskey J, Gollerkeri A, Perea R, Chutake Y, Agarwal S, Henrick P, Shi K, Daver N. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL). Journal Of Clinical Oncology 2024, 42: 3084-3084. DOI: 10.1200/jco.2024.42.16_suppl.3084.
- Bewersdorf J, Shimony S, Shallis R, Liu Y, Berton G, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Bystrom R, Lindsley R, Chen E, Ramos J, Stein A, Pullarkat V, Aldoss I, DeAngelo D, Neuberg D, Stone R, Garciaz S, Ball B, Stahl M. Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study. American Journal Of Hematology 2024, 99: 1640-1643. PMID: 38751104, DOI: 10.1002/ajh.27366.
- Bewersdorf J, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Stahl M, Stein E, Huntington S, Goshua G, Zeidan A. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1136-1144. PMID: 38648559, PMCID: PMC11265977, DOI: 10.1080/10428194.2024.2344052.
- Shimony S, Garcia J, Keating J, Chen E, Luskin M, Stahl M, Neuberg D, DeAngelo D, Stone R, Lindsley R. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 2024, 38: 1494-1500. PMID: 38538860, PMCID: PMC11216982, DOI: 10.1038/s41375-024-02230-w.
- Shimony S, Bewersdorf J, Shallis R, Liu Y, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Lindsley R, Chen E, Ramos Perez J, Stein A, DeAngelo D, Neuberg D, Stone R, Ball B, Stahl M. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 2024, 38: 762-768. PMID: 38378841, DOI: 10.1038/s41375-024-02175-0.
- Lane A, Garcia J, Raulston E, Garzon J, Galinsky I, Baxter E, Leonard R, DeAngelo D, Luskin M, Reilly C, Stahl M, Stone R, Vedula R, Wadleigh M, Winer E, Mughal T, Brooks C, Gupta I, Stevenson K, Neuberg D, Ren S, Keating J, Konopleva M, Stein A, Pemmaraju N. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Advances 2024, 8: 591-602. PMID: 38052038, PMCID: PMC10837492, DOI: 10.1182/bloodadvances.2023011721.
- Carlson K, Cunningham A, Stahl M, Winer E, Michaelis L. Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems? Acta Haematologica 2023, 147: 122-133. PMID: 38071966, DOI: 10.1159/000535607.
- Jann J, Hergott C, Winkler M, Liu Y, Braun B, Charles A, Copson K, Barua S, Meggendorfer M, Nadarajah N, Shimony S, Winer E, Wadleigh M, Stone R, DeAngelo D, Garcia J, Haferlach T, Lindsley C, Luskin M, Stahl M, Tothova Z. Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes. Blood 2023, 142: 999. DOI: 10.1182/blood-2023-187519.
- Luskin M, Shimony S, Keating J, Stock W, Hock H, Garcia J, Stahl M, Galinksy I, Leonard R, Weiner H, Flamand Y, Neuberg D, Stone R, Letai A, Winer E, Konopleva M, Jain N, DeAngelo D. Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL. Blood 2023, 142: 2875. DOI: 10.1182/blood-2023-174269.
- Bewersdorf J, Shimony S, Shallis R, Liu Y, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Lindsley R, Chen E, Ramos J, Stein A, DeAngelo D, Neuberg D, Stone R, Ball B, Stahl M. Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study. Blood 2023, 142: 1589. DOI: 10.1182/blood-2023-174283.
- Shimony S, Bewersdorf J, Shallis R, Liu Y, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Chen E, Ramos J, Lindsley R, Stein A, DeAngelo D, Neuberg D, Stone R, Ball B, Stahl M. What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study. Blood 2023, 142: 1478. DOI: 10.1182/blood-2023-172763.
- Bale S, Kim C, How J, Wazir M, Weeks L, Stahl M, Luskin M, DeAngelo D, Lindsley C, Kim A, Mullally A, Marneth A. Mutations in the RNA Splicing Factors U2AF1 and SRSF2 are Context-Dependent in Myeloproliferative Neoplasms. Blood 2023, 142: 1788. DOI: 10.1182/blood-2023-178657.
- Daver N, Stein A, Bixby D, Chai-Ho W, Zeidner J, Maher K, Stevens D, Stahl M, Yee K, Curran E, Ito S, Sochacki A, Sallman D, Hernandez R, Metenou S, Ma B, Kato K, Zeidan A. Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts). Blood 2023, 142: 4278. DOI: 10.1182/blood-2023-173991.
- No Increased Incidence of Bleeding in Essential Thrombocythemia Patients with Extreme ThrombocytosisVenkat R, Redd R, Aryee M, Marneth A, Kamaz B, Kim C, Wazir M, Weeks L, Stahl M, DeAngelo D, Lindsley C, Luskin M, Hobbs G, How J. No Increased Incidence of Bleeding in Essential Thrombocythemia Patients with Extreme Thrombocytosis. Blood 2023, 142: 1839. DOI: 10.1182/blood-2023-187530.
- Winer E, Garcia J, Stone R, Wadleigh M, Luskin M, Stahl M, Chen E, Leonard R, Noyes A, Galinsky I, Deshpande R, Borderies P, O'Neill V, DeAngelo D. Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 2023, 142: 1549. DOI: 10.1182/blood-2023-186598.
- Shimony S, Garcia J, Keating J, Chen E, Luskin M, Stahl M, Neuberg D, DeAngelo D, Stone R, Lindsley R. Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax. Blood 2023, 142: 977. DOI: 10.1182/blood-2023-173935.
- Garcia-Manero G, Ooi M, Lao Z, Gill H, Abaza Y, Stahl M, Haque T, DeZern A, Greenberg P, Pelletier M, Singh A, Carreon D, Beaulieu V, Woo J. Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study. Blood 2023, 142: 3250. DOI: 10.1182/blood-2023-174642.
- Volpe V, Luskin M, Stahl M, Lindsley C, DeAngelo D. Common Pathways for Acute Myeloid Leukemia Progression in Systemic Mastocytosis with Associated Hematologic Neoplasm. Blood 2023, 142: 6400. DOI: 10.1182/blood-2023-184587.
- How J, Leiva O, Marneth A, Kamaz B, Kim C, Weeks L, Wazir M, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hobbs G. Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes. Blood 2023, 142: 4568. DOI: 10.1182/blood-2023-179324.
- Luskin M, Murakami M, Keating J, Winer E, Garcia J, Stahl M, Wadleigh M, Flamand Y, Neuberg D, Galinsky I, Leonard R, Hagopian E, Weizer C, McLanahan C, Stone R, Wang E, Stock W, DeAngelo D. A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults. Blood 2023, 142: 965. DOI: 10.1182/blood-2023-174246.
- Osei M, Merz L, Chien K, Hammond D, Lindsley C, Luskin M, Stahl M, How J, Wazir M, Marneth A, Shimony S, Mullally A, DeAngelo D, Garcia-Manero G, Achebe M, Ebert B, Weeks L. Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs). Blood 2023, 142: 2427. DOI: 10.1182/blood-2023-172992.
- Lane A, Garcia J, Raulston E, Garzon J, Galinsky I, Baxter E, Leonard R, DeAngelo D, Luskin M, Reilly C, Stahl M, Stone R, Vedula R, Wadleigh M, Winer E, Mughal T, Brooks C, Gupta I, Stevenson K, Neuberg D, Ren S, Konopleva M, Stein A, Pemmaraju N. Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial. Blood 2023, 142: 4277. DOI: 10.1182/blood-2023-180010.
- How J, Marneth A, Kamaz B, Kim C, Neuberg D, Ren S, Wazir M, Weeks L, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hormoz S, Mullally A. Unlike TET2 and ASXL1, Co-Occurring DNMT3A Mutations Are Not Associated with Increased Age in JAK2-Mutant Myeloproliferative Neoplasms (MPNs). Blood 2023, 142: 4521. DOI: 10.1182/blood-2023-179407.
- Bewersdorf J, Shimony S, Shallis R, Liu Y, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Lindsley R, Chen E, Ramos J, Stein A, DeAngelo D, Neuberg D, Stone R, Ball B, Stahl M. Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study. Blood 2023, 142: 2964. DOI: 10.1182/blood-2023-174285.
- Rolles B, De Oliveira Filho C, Keating J, Luskin M, DeAngelo D, Lindsley C, Kim A, Hem J, Kim C, Weeks L, Wazir M, How J, Marneth A, Liu Y, Aryee M, Tsai H, Stahl M, Mullally A. TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms. Blood 2023, 142: 3160. DOI: 10.1182/blood-2023-185024.
- Kewan T, Bewersdorf J, Gurnari C, Xie Z, Stahl M, Zeidan A. When to use which molecular prognostic scoring system in the management of patients with MDS? Best Practice & Research Clinical Haematology 2023, 36: 101517. PMID: 38092484, DOI: 10.1016/j.beha.2023.101517.
- Bewersdorf J, Stahl M, Taylor J, Mi X, Chandhok N, Watts J, Derkach A, Wysocki M, Lu S, Bourcier J, Hogg S, Rahman J, Chaudhry S, Totiger T, Abdel-Wahab O, Stein E. E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia 2023, 37: 2512-2516. PMID: 37814121, PMCID: PMC10681888, DOI: 10.1038/s41375-023-02050-4.
- Shimony S, Fell G, Chen E, Tsai H, Wadleigh M, Winer E, Garcia J, Luskin M, Stahl M, Neuberg D, DeAngelo D, Lindsley R, Stone R. FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients age ≥60 years. Blood Advances 2023, 7: 5354-5358. PMID: 37163357, PMCID: PMC10509660, DOI: 10.1182/bloodadvances.2023009748.
- Santinelli E, Pascale M, Xie Z, Badar T, Stahl M, Bewersdorf J, Gurnari C, Zeidan A. Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution. Blood Reviews 2023, 62: 101130. PMID: 37679263, DOI: 10.1016/j.blre.2023.101130.
- Stahl M, Bewersdorf J, Xie Z, Porta M, Komrokji R, Xu M, Abdel-Wahab O, Taylor J, Steensma D, Starczynowski D, Sekeres M, Sanz G, Sallman D, Roboz G, Platzbecker U, Patnaik M, Padron E, Odenike O, Nimer S, Nazha A, Majeti R, Loghavi S, Little R, List A, Kim T, Hourigan C, Hasserjian R, Halene S, Griffiths E, Gore S, Greenberg P, Figueroa M, Fenaux P, Efficace F, DeZern A, Daver N, Churpek J, Carraway H, Buckstein R, Brunner A, Boultwood J, Borate U, Bejar R, Bennett J, Wei A, Santini V, Savona M, Zeidan A. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews 2023, 62: 101128. PMID: 37704469, DOI: 10.1016/j.blre.2023.101128.
- Sherban A, Fredman D, Shimony S, Yeshurun M, Raanani P, Stahl M, Gafter-Gvili A, Wolach O. Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML – A systematic review. Leukemia Research 2023, 133: 107368. PMID: 37598660, DOI: 10.1016/j.leukres.2023.107368.
- Stahl M, Giblin G, Liu Y, Winer E, Garcia J, Chen E, Wadleigh M, Ling K, Lindsley R, Shimony S, Copson K, Charles A, DeAngelo D, Stone R, Nohria A, Luskin M. Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia. Leukemia Research 2023, 132: 107351. PMID: 37451200, DOI: 10.1016/j.leukres.2023.107351.
- Rotter L, Shimony S, Ling K, Chen E, Shallis R, Zeidan A, Stahl M. Epidemiology and Pathogenesis of Myelodysplastic Syndrome. The Cancer Journal 2023, 29: 111-121. PMID: 37195766, DOI: 10.1097/ppo.0000000000000665.
- Stempel J, Xie Z, Bewersdorf J, Stahl M, Zeidan A. Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms. The Cancer Journal 2023, 29: 203-211. PMID: 37195777, DOI: 10.1097/ppo.0000000000000666.
- Bewersdorf J, Xie Z, Bejar R, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, Porta M, DeZern A, Fenaux P, Figueroa M, Gore S, Griffiths E, Halene S, Hasserjian R, Hourigan C, Kim T, Komrokji R, Kuchroo V, List A, Loghavi S, Majeti R, Odenike O, Patnaik M, Platzbecker U, Roboz G, Sallman D, Santini V, Sanz G, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Xu M, Savona M, Wei A, Zeidan A. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Reviews 2023, 60: 101072. PMID: 36934059, DOI: 10.1016/j.blre.2023.101072.
- Badar T, Atallah E, Shallis R, Saliba A, Patel A, Bewersdorf J, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg A, Abaza Y, Murthy G, Kota V, Litzow M. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia 2023, 37: 799-806. PMID: 36807649, DOI: 10.1038/s41375-023-01847-7.
- Frumm S, Shimony S, Stone R, DeAngelo D, Bewersdorf J, Zeidan A, Stahl M. Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. Blood Reviews 2023, 60: 101056. PMID: 36805300, DOI: 10.1016/j.blre.2023.101056.
- Shimony S, Stahl M, Stone R. Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management. American Journal Of Hematology 2023, 98: 502-526. PMID: 36594187, DOI: 10.1002/ajh.26822.
- Badar T, Litzow M, Shallis R, Patel A, Saliba A, Burkart M, Bewersdorf J, Stahl M, De Camargo Correia G, Murthy S, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg A, Palmisiano N, Al Kali A, Atallah E. Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia. Cancer 2022, 129: 934-945. PMID: 36545710, DOI: 10.1002/cncr.34604.
- Przespolewski A, Goldberg A, Talati C, Fazal S, Vachhani P, Sanikommu S, Thota S, Waksal J, Ball B, Famulare C, Stahl M, Baron J, Griffiths E, Thompson J, Sweet K, Wang E. Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia. Blood 2022, 141: 1489-1493. PMID: 36493344, DOI: 10.1182/blood.2022016678.
- Bewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stein E, Huntington S, Zeidan A. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia. Leukemia & Lymphoma 2022, 64: 454-461. PMID: 36493798, PMCID: PMC9957935, DOI: 10.1080/10428194.2022.2140288.
- Shimony S, Fell G, Chen E, Tsai H, Wadleigh M, Winer E, Garcia J, Luskin M, Stahl M, Neuberg D, DeAngelo D, Lindsley R, Stone R. FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3-wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study. Blood 2022, 140: 8938-8939. DOI: 10.1182/blood-2022-162716.
- Sherban A, Fredman D, Shimony S, Yeshurun M, Raanani P, Stahl M, Gafter-Gvili A, Wolach O. Safety and Efficacy of FLAG-Ida Combined with Venetoclax Treatment for Newly Diagnosed and Relapsed / Refractory AML Patients- a Systematic Review. Blood 2022, 140: 11716-11717. DOI: 10.1182/blood-2022-163152.
- Badar T, Atallah E, Saliba A, Shallis R, Stahl M, Bewersdorf J, De Camargo Correia G, Patel A, Abaza Y, Murthy S, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kota V, Dinner S, Goldberg A, Litzow M. Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2022, 140: 6058-6060. DOI: 10.1182/blood-2022-163795.
- Badar T, Atallah E, Shallis R, Saliba A, Stahl M, Bewersdorf J, Grenet J, Patel A, Abaza Y, Murthy S, Duvall A, Burkart M, Palmisiano N, Kubiak M, Kota V, Dinner S, Goldberg A, Litzow M. Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2022, 140: 1435-1437. DOI: 10.1182/blood-2022-167731.
- Winer E, Flamand Y, Shallis R, Stempel J, Goldberg A, Stahl M, Patel A, Duvall A, Abaza Y, Oh T, Ma K, Badar T, Litzow M, Kota V, Bradshaw D, Raman H, Luskin M, Stone R, DeAngelo D. Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhigh but Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age. Blood 2022, 140: 6285-6287. DOI: 10.1182/blood-2022-170587.
- Bewersdorf J, Stahl M, Taylor J, Chandhok N, Watts J, Derkach A, Wysocki M, Kostantakis V, Lu S, Bourcier J, Hogg S, Totiger T, Abdel-Wahab O, Stein E. A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes. Blood 2022, 140: 9065-9067. DOI: 10.1182/blood-2022-156830.
- Bewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stempel J, Stein E, Huntington S, Zeidan A. Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid Leukemia. Blood 2022, 140: 319-321. DOI: 10.1182/blood-2022-158465.
- Bewersdorf J, Grimshaw A, Platzbecker U, Fenaux P, Sekeres M, Zeidan A, Stahl M. International Working Group (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents - a Systematic Review and Meta-Analysis. Blood 2022, 140: 9811-9812. DOI: 10.1182/blood-2022-158622.
- Marneth A, Jutzi J, Kim C, Laurore C, Tishena A, Kramer F, Rocha A, Wazir M, Weeks L, How J, Stahl M, Luskin M, Lindsley R, Pozdnyakova O, Graubert T, Mullally A. Mutant Srsf2 Diminishes Jak2V617F -Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2-Mutant MPN. Blood 2022, 140: 1089-1090. DOI: 10.1182/blood-2022-158823.
- Stahl M, Giblin G, Liu Y, DeAngelo D, Stone R, Winer E, Wadleigh M, Lindsley C, Shimony S, Copson K, Charles A, Nohria A, Luskin M. Genetic Predictors of Anthracycline Mediated Cardiomyopathy with Induction Chemotherapy in Acute Myeloid Leukemia (AML). Blood 2022, 140: 6067-6068. DOI: 10.1182/blood-2022-159193.
- Xie Z, Chen E, Stahl M, Zeidan A. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age. Blood Reviews 2022, 59: 101033. PMID: 36357283, DOI: 10.1016/j.blre.2022.101033.
- Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia 2022, 36: 2934-2938. PMID: 36335264, DOI: 10.1038/s41375-022-01754-3.
- Stahl M, Derkach A, Farnoud N, Bewersdorf J, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel M, Cai S, Miles L, Bowman R, Geyer M, Dunbar A, Epstein‐Peterson Z, McGovern E, Schulman J, Glass J, Taylor J, Viny A, Stein E, Getta B, Arcila M, Gao Q, Barker J, Shaffer B, Papadopoulos E, Gyurkocza B, Perales M, Abdel‐Wahab O, Levine R, Giralt S, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman M, Roshal M, Goldberg A. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. American Journal Of Hematology 2022, 98: 79-89. PMID: 36251406, PMCID: PMC10080561, DOI: 10.1002/ajh.26757.
- Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. Leukemia & Lymphoma 2022, 64: 188-196. PMID: 36287540, PMCID: PMC9905301, DOI: 10.1080/10428194.2022.2136952.
- Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 2022, 36: 2939-2946. PMID: 36266326, DOI: 10.1038/s41375-022-01724-9.
- Stahl M, Shallis R, Derkach A, Goldberg A, Stein A, Stein E, Marcucci G, Zeidan A, Shimony S, DeAngelo D, Stone R, Aldoss I, Ball B, Bewersdorf J. Poster: AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma & Leukemia 2022, 22: s128. DOI: 10.1016/s2152-2650(22)00761-3.
- Stahl M, Shallis R, Derkach A, Goldberg A, Stein A, Stein E, Marcucci G, Zeidan A, Shimony S, DeAngelo D, Stone R, Aldoss I, Ball B, Bewersdorf J. AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma & Leukemia 2022, 22: s209-s210. DOI: 10.1016/s2152-2650(22)01214-9.
- Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. Leukemia Research 2022, 122: 106942. PMID: 36108424, DOI: 10.1016/j.leukres.2022.106942.
- Shimony S, Rozental A, Bewersdorf J, Goldberg A, Stein E, Grimshaw A, Stone R, DeAngelo D, Wolach O, Stahl M. Investigational venetoclax combination therapy in acute myeloid leukemia – a systematic review and meta-analysis. Haematologica 2022, 107: 2955-2960. PMID: 36453519, PMCID: PMC9713559, DOI: 10.3324/haematol.2022.281453.
- Badar T, Litzow M, Shallis R, Stahl M, Bewersdorf J, Saliba A, de Camargo Correia G, Patel A, Abaza Y, Murthy S, Duvall A, Burkart M, Al-Kali A, Palmisiano N, Dinner S, Goldberg A, Atallah E. Racial disparities in patients with TP53 mutated acute myeloid leukemia. Journal Of Clinical Oncology 2022, 40: e19007-e19007. DOI: 10.1200/jco.2022.40.16_suppl.e19007.
- Shallis RM, Bewersdorf JP, Stahl MF, Halene S, Zeidan AM. Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia? Cancers 2022, 14: 2434. PMID: 35626039, PMCID: PMC9140008, DOI: 10.3390/cancers14102434.
- Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JM. Outcomes of TP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. American Journal Of Hematology 2022, 97: e232-e235. PMID: 35338673, DOI: 10.1002/ajh.26546.
- North K, Benbarche S, Liu B, Pangallo J, Chen S, Stahl M, Bewersdorf J, Stanley R, Erickson C, Cho H, Pineda J, Thomas J, Polaski J, Belleville A, Gabel A, Udy D, Humbert O, Kiem H, Abdel-Wahab O, Bradley R. Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. Nature Biotechnology 2022, 40: 1103-1113. PMID: 35241838, PMCID: PMC9288984, DOI: 10.1038/s41587-022-01224-2.
- Shimony S, Stone R, Stahl M. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. Current Opinion In Hematology 2021, 29: 63-73. PMID: 34966123, DOI: 10.1097/moh.0000000000000698.
- Shallis R, Stahl M, Bewersdorf J, Zeidan A. The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia. Hemato 2021, 2: 748-763. DOI: 10.3390/hemato2040051.
- Grenet J, Jain A, Burkart M, Waksal J, Famulare C, Numan Y, Stahl M, Mckinnell Z, Ball B, Ma X, Christos P, Ritchie E, Samuel M, Kaner J, Lee S, Goldberg A, Dinner S, Sweet K, Roboz G, Desai P. Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia. Blood 2021, 138: 32. DOI: 10.1182/blood-2021-145947.
- Desai P, Goldberg A, Anderson K, Narendra V, Neuberg D, Radhakrishnan V, Redd R, Roboz G, Sehn L, Sekeres M, Stahl M, Tallman M, Thompson J, Tucker E, Wood W, Hicks L. Clinical Predictors of Outcome in Adult Patients with Acute Leukemias and Myelodysplastic Syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub. Blood 2021, 138: 280. PMCID: PMC8701680, DOI: 10.1182/blood-2021-146016.
- Wang E, Pineda J, Bourcier J, Stahl M, Penson A, Wakiro I, Singer M, Cui D, Erickson C, Knorr K, Stanley R, Chen X, McMillan E, Bossard C, Aifantis I, Bradley R, Abdel-Wahab O. Modulation of RNA Splicing Enhances Response to BCL2 Inhibition in Acute Myeloid Leukemia. Blood 2021, 138: 507. DOI: 10.1182/blood-2021-146373.
- Badar T, Litzow M, Shallis R, Bewersdorf J, Saliba A, De Camargo Correia G, Stahl M, Goldberg A, Atallah E, Foran J. Multicenter Analysis of Treatment and Outcomes for Patient with TP53 Mutated AML in the Era of Novel Therapies; Significant Impact of Allogeneic Stem Cell Transplantation on Survival. Blood 2021, 138: 797. DOI: 10.1182/blood-2021-147639.
- Myers R, Izzo F, Prieto T, Mimitou E, Raviram R, Chaligne R, Hoffman R, Stahl M, Abdel-Wahab O, Marcellino B, Smibert P, Landau D. High Throughput Single-Cell Simultaneous Genotyping and Chromatin Accessibility Reveals Genotype to Phenotype Relationship in Human Myeloproliferation. Blood 2021, 138: 678. DOI: 10.1182/blood-2021-149226.
- Przespolewski A, Goldberg A, Talati C, Fazal S, Vachhani P, Sanikommu S, Thota S, Waksal J, Ball B, Famulare C, Stahl M, Mckinnell Z, Baron J, Griffiths E, Thompson J, Sweet K, Wang E. Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis. Blood 2021, 138: 1264. DOI: 10.1182/blood-2021-153791.
- Hicks L, Redd R, Anderson K, Desai P, Dolan B, Goldberg A, Narendra V, Neuberg D, Radhakrishnan V, Sehn L, Sekeres M, Stahl M, Tallman M, Thompson J, Tucker E, Wood W. Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology. Blood 2021, 138: 3040. PMCID: PMC8701544, DOI: 10.1182/blood-2021-154283.
- King A, Weis T, Derkach A, Ball S, Pandey M, Mauro M, Goldberg A, Stahl M, Famulare C, Tallman M, Wang E, Kuykendall A, Rampal R. Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. American Journal Of Hematology 2021, 97: e7-e10. PMID: 34674293, DOI: 10.1002/ajh.26381.
- Bewersdorf J, Stone R, Tallman M, Stahl M. Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML? Leukemia & Lymphoma 2021, 62: 3318-3319. PMID: 34587866, DOI: 10.1080/10428194.2021.1986220.
- Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 997.e1-997.e11. PMID: 34551341, PMCID: PMC9533376, DOI: 10.1016/j.jtct.2021.09.005.
- Bewersdorf J, Tallman M, Stahl M. Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept. Current Opinion In Oncology 2021, 33: 658-669. PMID: 34341323, DOI: 10.1097/cco.0000000000000778.
- Stahl M, Tallman M, Goldberg A. Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey. Leukemia & Lymphoma 2021, 62: 2050-2051. PMID: 34519611, DOI: 10.1080/10428194.2021.1929967.
- Stahl M, Narendra V, Jee J, Derkach A, Maloy M, Geyer M, Mato A, Roeker L, Tallman M, Shah G, Daniyan A, Goldberg A. Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leukemia & Lymphoma 2021, 62: 1940-1948. PMID: 34180767, PMCID: PMC10080398, DOI: 10.1080/10428194.2021.1885664.
- Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 873.e1-873.e13. PMID: 34052505, PMCID: PMC8478722, DOI: 10.1016/j.jtct.2021.05.016.
- Xiao W, Chan A, Waarts M, Mishra T, Liu Y, Cai S, Yao J, Gao Q, Bowman R, Koche R, Csete I, DelGaudio N, Derkach A, Baik J, Yanis S, Famulare C, Patel M, Arcila M, Stahl M, Rampal R, Tallman M, Zhang Y, Dogan A, Goldberg A, Roshal M, Levine R. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood 2021, 137: 1377-1391. PMID: 32871587, PMCID: PMC7955409, DOI: 10.1182/blood.2020007897.
- Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King A, Daniyan A, Famulare C, Cuello B, Horvat T, Abdel-Wahab O, Levine R, Viny A, Stein E, Cai S, Roshal M, Tallman M, Goldberg A. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances 2021, 5: 1552-1564. PMID: 33687434, PMCID: PMC7948282, DOI: 10.1182/bloodadvances.2020003734.
- Pollyea D, Stahl M, Talati C, Asghari H, Lai C, Abedin S, Zeidner J, Muluneh B, Xavier M, Edwards W, Wolach O, Moshe Y, Lavie D, Zuckerman T, Choi M, Bui C, Svensson A, Kye S, Burne R, Guerin A, Ma E, Montez M, Goldberg A. Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative. Blood 2020, 136: 26-28. DOI: 10.1182/blood-2020-134789.
- Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King A, Daniyan A, Famulare C, Cuello B, Abdel-Wahab O, Levine R, Viny A, Stein E, Roshal M, Tallman M, Goldberg A. Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors. Blood 2020, 136: 47-48. DOI: 10.1182/blood-2020-137815.
- Bewersdorf J, Tallman M, Cho C, Zeidan A, Stahl M. Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis. Blood 2020, 136: 34-35. DOI: 10.1182/blood-2020-136671.
- Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. International Journal Of Hematology 2020, 113: 92-99. PMID: 32951163, DOI: 10.1007/s12185-020-02994-8.
- Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis. Leukemia 2020, 35: 1643-1660. PMID: 32868875, PMCID: PMC7917159, DOI: 10.1038/s41375-020-01020-4.
- Stahl M, Epstein-Peterson Z, Intlekofer A. Oncogenic Mechanisms and Therapeutic Targeting of Metabolism in Leukemia and Lymphoma. Cold Spring Harbor Perspectives In Medicine 2020, 11: a035477. PMID: 32816875, PMCID: PMC8247556, DOI: 10.1101/cshperspect.a035477.
- Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, Stahl M. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta‐analysis. Transfusion 2020, 60: 2360-2369. PMID: 32776542, PMCID: PMC8631180, DOI: 10.1111/trf.15994.
- Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, Tallman MS, Zeidan AM, Stahl M. Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma & Leukemia 2020, 20: e712-e723. PMID: 32669244, PMCID: PMC7541411, DOI: 10.1016/j.clml.2020.05.018.
- Shallis RM, Stahl M, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Review Of Hematology 2020, 13: 489-499. PMID: 32248712, DOI: 10.1080/17474086.2020.1751609.
- Stahl M, Tallman M. Late and very late relapses in acute myeloid leukemia (AML). Leukemia & Lymphoma 2020, 61: 1010-1011. PMID: 32283963, DOI: 10.1080/10428194.2020.1745204.
- Pine AB, Chokr N, Stahl M, Steensma DP, Sekeres MA, Litzow MR, Luger SM, Stone RM, Greenberg PL, Bejar R, Bewersdorf JP, Gore SD, Zeidan AM. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leukemia & Lymphoma 2020, 61: 1455-1464. PMID: 32026740, DOI: 10.1080/10428194.2020.1723013.
- Stahl M, Tallman M. Outcomes of allogeneic stem cell transplantation for patients with t(6:9) AML‐ A strong case for allogeneic stem cell transplantation in first complete remission. British Journal Of Haematology 2020, 189: 806-808. PMID: 31999852, DOI: 10.1111/bjh.16478.
- Bewersdorf JP, Giri S, Wang R, Williams RT, Tallman MS, Zeidan AM, Stahl M. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica 2020, 105: 2659-2663. PMID: 33131256, PMCID: PMC7604631, DOI: 10.3324/haematol.2019.242826.
- Agrawal V, Gbolahan OB, Stahl M, Zeidan AM, Zaid MA, Farag SS, Konig H. Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia. Current Cancer Drug Targets 2020, 20: 473-489. PMID: 32357813, DOI: 10.2174/1568009620666200502011059.
- Stahl M, Tallman M. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leukemia & Lymphoma 2019, 60: 3107-3115. PMID: 31842650, PMCID: PMC7479633, DOI: 10.1080/10428194.2019.1613540.
- Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2019, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.
- Stahl M, Tallman M. Differentiation syndrome in acute promyelocytic leukaemia. British Journal Of Haematology 2019, 187: 157-162. PMID: 31410848, DOI: 10.1111/bjh.16151.
- Bewersdorf JP, Stahl M, Zeidan AM. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant. Expert Review Of Hematology 2019, 12: 575-578. PMID: 31225770, DOI: 10.1080/17474086.2019.1635005.
- Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leukemia & Lymphoma 2019, 60: 3181-3187. PMID: 31170846, DOI: 10.1080/10428194.2019.1622700.
- Stahl M, Tallman M. Antibody-based therapy in acute leukemia - beware the risks. Leukemia & Lymphoma 2019, 60: 1608-1609. PMID: 31204877, DOI: 10.1080/10428194.2019.1608535.
- Stahl M, Bewersdorf J, Giri S, Wang R, Zeidan AM. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica 2019, 105: 102-111. PMID: 31004015, PMCID: PMC6939518, DOI: 10.3324/haematol.2019.219345.
- Chokr N, Pine AB, Bewersdorf JP, Shallis RM, Stahl M, Zeidan AM. Getting personal with myelodysplastic syndromes: is now the right time? Expert Review Of Hematology 2019, 12: 215-224. PMID: 30977414, PMCID: PMC6540985, DOI: 10.1080/17474086.2019.1592673.
- Stahl M, Goldberg A. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets. Current Oncology Reports 2019, 21: 37. PMID: 30904967, DOI: 10.1007/s11912-019-0781-7.
- Zeidan A, Hu X, Zhu W, Stahl M, Giri S, Huntington S, Wang R, Podoltsev N, Gore S, Ma X, Davidoff A. Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis. Blood 2018, 132: 370. DOI: 10.1182/blood-2018-99-111052.
- Pine A, Chokr N, Stahl M, Steensma D, Sekeres M, Litzow M, Luger S, Stone R, Greenberg P, Bejar R, Gore S, Zeidan A. Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey. Blood 2018, 132: 1825. DOI: 10.1182/blood-2018-99-113888.
- Zeidan A, Zhu W, Wang R, Stahl M, Huntington S, Giri S, Podoltsev N, Gore S, Ma X, Davidoff A. Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions. Blood 2018, 132: 838. DOI: 10.1182/blood-2018-99-116497.
- Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review Of Hematology 2018, 11: 715-726. PMID: 30024293, DOI: 10.1080/17474086.2018.1503049.
- Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study. Journal Of Clinical Oncology 2017, 35: 7057-7057. DOI: 10.1200/jco.2017.35.15_suppl.7057.
- Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. 121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based Study. Leukemia Research 2017, 55: s75-s76. DOI: 10.1016/s0145-2126(17)30234-5.
- Stahl M, Zeidan AM. Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel? Cancer 2017, 123: 911-914. PMID: 28094843, DOI: 10.1002/cncr.30532.
- Stahl M, Kim TK, Zeidan AM. Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World Journal Of Stem Cells 2016, 8: 316-331. PMID: 27822339, PMCID: PMC5080639, DOI: 10.4252/wjsc.v8.i10.316.
- Stahl M, Kohrman N, Gore SD, Kim TK, Zeidan AM, Prebet T. Epigenetics in Cancer: A Hematological Perspective. PLOS Genetics 2016, 12: e1006193. PMID: 27723796, PMCID: PMC5065123, DOI: 10.1371/journal.pgen.1006193.
- Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Reviews 2016, 31: 43-62. PMID: 27745715, DOI: 10.1016/j.blre.2016.09.005.
- Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. Annals Of Hematology 2016, 95: 1895-1898. PMID: 27468851, PMCID: PMC10955604, DOI: 10.1007/s00277-016-2761-4.
- Stahl M, Gedrich R, Peck R, LaVallee T, Eder JP. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors. Immunotherapy 2016, 8: 767-774. PMID: 27349976, DOI: 10.2217/imt-2016-0040.
- Suozzi KC, Stahl M, Ko CJ, Chiang A, Gettinger SN, Siegel MD, Bunick CG. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Reports 2016, 2: 264-268. PMID: 27486590, PMCID: PMC4949498, DOI: 10.1016/j.jdcr.2016.05.002.
- Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Annals Of Hematology 2016, 95: 1197-1200. PMID: 27068405, PMCID: PMC7479634, DOI: 10.1007/s00277-016-2664-4.
- Stahl M, Mohareb AM, Lee AI, Federman DG, Siddon AJ, Spelman J. Multi‐system complications of hypereosinophilia. American Journal Of Hematology 2016, 91: 444-447. PMID: 26700720, DOI: 10.1002/ajh.24283.
- Stahl M, Gore SD, Vey N, Prebet T. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Expert Opinion On Investigational Drugs 2016, 25: 307-317. PMID: 26807602, DOI: 10.1517/13543784.2016.1146251.
- Stahl K, Stahl M, de Jonge HR, Forrest JN. ANP and CNP activate CFTR expressed in Xenopus laevis oocytes by direct activation of PKA. Journal Of Receptors And Signal Transduction 2015, 35: 493-504. PMID: 26016495, DOI: 10.3109/10799893.2015.1015738.
- Stahl M, Stahl K, Brubacher MB, Forrest JN. Divergent CFTR orthologs respond differently to the channel inhibitors CFTRinh-172, glibenclamide, and GlyH-101. American Journal Of Physiology - Cell Physiology 2011, 302: c67-c76. PMID: 21940661, PMCID: PMC3328903, DOI: 10.1152/ajpcell.00225.2011.
- Blood 2016 128:1063;The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort
Locations
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl NP7
New Haven, CT 06511
- Smilow Cancer Hospital at Yale New Haven35 Park Street, Fl NP7New Haven, CT 06511
Titles
- Assistant Professor
- Director Leukemia and Myeloid Malignancy Program, Yale Cancer Center
- Chief Duffy Hematology Firm, Yale-New Haven Hospital
Education & Training
- Research FellowThe Rockefeller University (2021)
- Clinical FellowMemorial-Sloan Kettering Cancer Center (2021)
- Chief ResidentYale School of Medicine (2018)
- ResidentYale School of Medicine (2017)
- InternYale School of Medicine (2015)
- Post-doctoral FellowYale University (2014)
- MDHannover Medical School (2013)
Languages Spoken
- English
- Deutsch (German)
Additional Information
Honors & Recognitions
- Translational Research Program Award: Leukemia and Lymphoma Society (2023)
- Abstract achievement award : American Society of Hematology (2020)
- Abstract achievement award : American Society of Hematology (2017)
- Stephen R. Shell Award: Yale University (2017)
- HONORS award: American Society of Hematology (2017)
- Abstract achievement award : American Society of Hematology (2016)
- Samuel D. Kuslan Award : Yale University (2016)
- Full Academic Scholarship: German National Academic Scholarship Foundation (Studienstiftung des Deutschen Volkes) (2006)
Board Certifications
- AB of Internal Medicine, Hematology (Internal Medicine) (2021)
- AB of Internal Medicine, Medical Oncology (2021)
- AB of Internal Medicine, Internal Medicine (2017)
Publications
- Bidikian A, Bewersdorf J, Kewan T, Podoltsev N, Stahl M, Zeidan A. Imetelstat in myeloid malignancies: current data and future directions. Expert Review Of Anticancer Therapy 2025, ahead-of-print: 1-12. PMID: 40116730, DOI: 10.1080/14737140.2025.2482721.
- Alhajahjeh A, Stahl M, Kim T, Kewan T, Stempel J, Zeidan A, Bewersdorf J. Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment. Expert Review Of Anticancer Therapy 2025, ahead-of-print: 1-22. PMID: 40122075, DOI: 10.1080/14737140.2025.2483855.
- Petit C, Higue J, Acheaibi Z, Gilhodes J, Hospital M, Devillier R, Bewersdorf J, Goldberg A, Pigneux A, Vey N, Récher C, Stahl M, Bertoli S, Dumas P, Garciaz S. Venetoclax–Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC‐DATAML‐MSKCC Retrospective Study. American Journal Of Hematology 2025, 100: 906-908. PMID: 40088036, DOI: 10.1002/ajh.27626.
- Shimony S, Stahl M, Stone R. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management. American Journal Of Hematology 2025, 100: 860-891. PMID: 39936576, PMCID: PMC11966364, DOI: 10.1002/ajh.27625.
- Luskin M, Murakami M, Keating J, Flamand Y, Winer E, Garcia J, Stahl M, Stone R, Wadleigh M, Jaeckle S, Hagopian E, Weinstock D, Liegel J, McMasters M, Wang E, Stock W, DeAngelo D. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia. Blood 2025, 145: 577-589. PMID: 39374521, DOI: 10.1182/blood.2024025800.
- How J, Leiva O, Redd R, Marneth A, DeAngelo D, Dieli-Conwright C, El-Jawahri A, Kamaz B, Kim C, Lindsley C, Luskin M, Stahl M, Wazir M, Weeks L, Hobbs G. Cardiovascular Risk Factors in Myeloproliferative Neoplasms: Associations with Survival and Thrombotic Outcomes. Blood Vessels Thrombosis & Hemostasis 2025, 100051. DOI: 10.1016/j.bvth.2025.100051.
- Bidikian A, Bewersdorf J, Kewan T, Stahl M, Zeidan A. Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them. Cancers 2024, 16: 4092. PMID: 39682277, PMCID: PMC11640703, DOI: 10.3390/cancers16234092.
- Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, 66: 488-496. PMID: 39560957, DOI: 10.1080/10428194.2024.2426073.
- A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDSNorman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, Stahl M, Eighmy W, Zeidan A. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Review Of Hematology 2024, 17: 755-767. PMID: 39474840, DOI: 10.1080/17474086.2024.2422554.
- Bewersdorf J, Hasle V, Shallis R, Thompson E, De Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab. Blood 2024, 144: 4585. DOI: 10.1182/blood-2024-194929.
- Chen E, Liu Y, Bell H, Galinsky I, Luskin M, Winer E, Stahl M, Vedula R, Volpe V, DeAngelo D, Quillen K, Ryan J, Minihane E, Hersch M, Leonard R, Neuberg D, Stone R, Letai A, Lane A, Garcia J. Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study. Blood 2024, 144: 4580-4580. DOI: 10.1182/blood-2024-198284.
- Zhang J, Shimony S, Liu Y, Inyang E, Chen E, Aguirre L, Bystrom R, Rolles B, Stone R, DeAngelo D, Tiao E, Stahl M. Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy. Blood 2024, 144: 5175-5175. DOI: 10.1182/blood-2024-200358.
- Alhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Goshua G, Bewersdorf J. Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia. Blood 2024, 144: 788. DOI: 10.1182/blood-2024-201535.
- Aguirre L, Bewersdorf J, Liu Y, Shallis R, Boussi L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Ling K, Chen E, Wadleigh M, Stein E, Goldberg A, Zeidan A, Shimony S, Stahl M. Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics. Blood 2024, 144: 4267-4267. DOI: 10.1182/blood-2024-202744.
- Shimony S, Wang Y, Cronin A, Walsh T, Charles A, Slopen N, Stahl M, Bystrom R, Luskin M, Abel G, DeAngelo D, Stone R, Lindsley R, Hantel A. Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group. Blood 2024, 144: 5171-5171. DOI: 10.1182/blood-2024-203644.
- Stone R, DeAngelo D, Letai A, Galinsky I, Weiner H, Halpin A, Noyes L, Smith H, Lombardi C, Leonard R, Fell G, Flammand Y, Ryan J, Konopleva M, Wadleigh M, Stahl M, Chen E, Volpe V, Winer E, Garcia J, Luskin M, Patel A. Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia. Blood 2024, 144: 4261. DOI: 10.1182/blood-2024-203683.
- Potnis K, Ito S, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Zeidan A, Bewersdorf J, Goshua G. Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States. Blood 2024, 144: 3644. DOI: 10.1182/blood-2024-204312.
- Boussi L, Bewersdorf J, Liu Y, Shallis R, Aguirre L, Zucenka A, Garciaz S, Bystrom R, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Ling K, Zeidan A, Goldberg A, Stein E, Shimony S, Stahl M. Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities. Blood 2024, 144: 4281-4281. DOI: 10.1182/blood-2024-204467.
- Bystrom R, Bewersdorf J, Liu Y, Schaefer E, Shallis R, Boussi L, Zucenka A, Garciaz S, Aguirre L, DeAngelo D, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Ling K, Stein E, Goldberg A, Zeidan A, Shimony S, Stahl M. The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study. Blood 2024, 144: 2947-2947. DOI: 10.1182/blood-2024-205581.
- Iat A, Bewersdorf J, Gilhodes J, Liu Y, Shallis R, Boussi L, Zucenka A, Bystrom R, DeAngelo D, Berton G, Soua A, Ling K, Aguirre L, Stone R, Luskin M, Garcia J, Winer E, Chen E, Wadleigh M, Goldberg A, Zeidan A, Cluzeau T, Shimony S, Stahl M, Garciaz S. Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia. Blood 2024, 144: 1508. DOI: 10.1182/blood-2024-207045.
- Chin K, Derkach A, Famulare C, Gupta G, Borge P, Geyer M, Goldberg A, Haque T, Park J, Roeker L, Tallman M, Stahl M, Stein E. HMA/Ven Treatment Modifications and Associated Outcomes in IDH -Mutant AML. Blood 2024, 144: 5962-5962. DOI: 10.1182/blood-2024-211733.
- Alhajahjeh A, Rotter L, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database. JCO Global Oncology 2024, 10: e2400316. PMID: 39621951, DOI: 10.1200/go-24-00316.
- Rotter L, Alhajahjeh A, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Analyzing determinants of premature trial discontinuation in leukemia clinical trials. Leukemia & Lymphoma 2024, 66: 289-297. PMID: 39440622, DOI: 10.1080/10428194.2024.2416565.
- Bidikian A, Bewersdorf J, Shallis R, Getz T, Stempel J, Kewan T, Stahl M, Zeidan A. Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions. Expert Review Of Anticancer Therapy 2024, 24: 1131-1146. PMID: 39367718, DOI: 10.1080/14737140.2024.2414071.
- Chin K, Derkach A, Famulare C, Gupta G, Borge P, Geyer M, Goldberg A, Haque T, Park J, Roeker L, Tallman M, Stahl M, Stein E. HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML. Leukemia & Lymphoma 2024, 66: 270-278. PMID: 39397429, DOI: 10.1080/10428194.2024.2411436.
- Venkat R, Redd R, Harris A, Aryee M, Marneth A, Kamaz B, Kim C, Wazir M, Weeks L, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hobbs G, How J. Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis. Blood Advances 2024, 8: 6043-6054. PMID: 39293089, PMCID: PMC11635702, DOI: 10.1182/bloodadvances.2024013777.
- Bewersdorf J, Shimony S, Shallis R, Liu Y, Berton G, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Bystrom R, Lindsley R, Chen E, Perez J, Stein A, Pullarkat V, Aldoss I, DeAngelo D, Neuberg D, Stone R, Garciaz S, Ball B, Stahl M. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML. Blood Advances 2024, 8: 4845-4855. PMID: 38941537, PMCID: PMC11416634, DOI: 10.1182/bloodadvances.2024012858.
- Getz T, Bewersdorf J, Kewan T, Stempel J, Bidikian A, Shallis R, Stahl M, Zeidan A. Beyond HMAs: Novel Targets and Therapeutic Approaches. Seminars In Hematology 2024, 61: 358-369. PMID: 39389839, DOI: 10.1053/j.seminhematol.2024.08.001.
- Jann J, Hergott C, Winkler M, Liu Y, Braun B, Charles A, Copson K, Barua S, Meggendorfer M, Nadarajah N, Shimony S, Winer E, Wadleigh M, Stone R, DeAngelo D, Garcia J, Haferlach T, Lindsley R, Luskin M, Stahl M, Tothova Z. Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia 2024, 38: 1992-2002. PMID: 39033241, PMCID: PMC11347381, DOI: 10.1038/s41375-024-02347-y.
- Alhajahjeh A, Bewersdorf J, Bystrom R, Zeidan A, Shimony S, Stahl M. Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome. Leukemia & Lymphoma 2024, 65: 1541-1551. PMID: 38962996, DOI: 10.1080/10428194.2024.2367040.
- Santini V, Stahl M, Sallman D. TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates. American Society Of Clinical Oncology Educational Book 2024, 44: e432650. PMID: 38768424, DOI: 10.1200/edbk_432650.
- Badar T, Nanaa A, Atallah E, Shallis R, Craver E, Li Z, Goldberg A, Saliba A, Patel A, Bewersdorf J, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy S, Zeidan A, Kota V, Patnaik M, Litzow M. Prognostic impact of ‘multi-hit’ versus ‘single-hit’ TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. Haematologica 2024, 109: 3533-3542. PMID: 38813716, PMCID: PMC11532685, DOI: 10.3324/haematol.2024.285000.
- Khawaja M, Naqash A, Schneider R, Shastri A, Stahl M, Moser J, Abdel Karim N, Madanat Y, Jonas B, Stein E, Gadgeel S, McCloskey J, Gollerkeri A, Perea R, Chutake Y, Agarwal S, Henrick P, Shi K, Daver N. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL). Journal Of Clinical Oncology 2024, 42: 3084-3084. DOI: 10.1200/jco.2024.42.16_suppl.3084.
- Bewersdorf J, Shimony S, Shallis R, Liu Y, Berton G, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Bystrom R, Lindsley R, Chen E, Ramos J, Stein A, Pullarkat V, Aldoss I, DeAngelo D, Neuberg D, Stone R, Garciaz S, Ball B, Stahl M. Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study. American Journal Of Hematology 2024, 99: 1640-1643. PMID: 38751104, DOI: 10.1002/ajh.27366.
- Bewersdorf J, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Stahl M, Stein E, Huntington S, Goshua G, Zeidan A. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1136-1144. PMID: 38648559, PMCID: PMC11265977, DOI: 10.1080/10428194.2024.2344052.
- Shimony S, Garcia J, Keating J, Chen E, Luskin M, Stahl M, Neuberg D, DeAngelo D, Stone R, Lindsley R. Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 2024, 38: 1494-1500. PMID: 38538860, PMCID: PMC11216982, DOI: 10.1038/s41375-024-02230-w.
- Shimony S, Bewersdorf J, Shallis R, Liu Y, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Lindsley R, Chen E, Ramos Perez J, Stein A, DeAngelo D, Neuberg D, Stone R, Ball B, Stahl M. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 2024, 38: 762-768. PMID: 38378841, DOI: 10.1038/s41375-024-02175-0.
- Lane A, Garcia J, Raulston E, Garzon J, Galinsky I, Baxter E, Leonard R, DeAngelo D, Luskin M, Reilly C, Stahl M, Stone R, Vedula R, Wadleigh M, Winer E, Mughal T, Brooks C, Gupta I, Stevenson K, Neuberg D, Ren S, Keating J, Konopleva M, Stein A, Pemmaraju N. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Advances 2024, 8: 591-602. PMID: 38052038, PMCID: PMC10837492, DOI: 10.1182/bloodadvances.2023011721.
- Carlson K, Cunningham A, Stahl M, Winer E, Michaelis L. Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems? Acta Haematologica 2023, 147: 122-133. PMID: 38071966, DOI: 10.1159/000535607.
- Jann J, Hergott C, Winkler M, Liu Y, Braun B, Charles A, Copson K, Barua S, Meggendorfer M, Nadarajah N, Shimony S, Winer E, Wadleigh M, Stone R, DeAngelo D, Garcia J, Haferlach T, Lindsley C, Luskin M, Stahl M, Tothova Z. Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes. Blood 2023, 142: 999. DOI: 10.1182/blood-2023-187519.
- Luskin M, Shimony S, Keating J, Stock W, Hock H, Garcia J, Stahl M, Galinksy I, Leonard R, Weiner H, Flamand Y, Neuberg D, Stone R, Letai A, Winer E, Konopleva M, Jain N, DeAngelo D. Mini-Hyper-CVD Plus Venetoclax for Treatment of Older Adults with Newly Diagnosed Ph-Negative B-ALL or T-ALL. Blood 2023, 142: 2875. DOI: 10.1182/blood-2023-174269.
- Bewersdorf J, Shimony S, Shallis R, Liu Y, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Lindsley R, Chen E, Ramos J, Stein A, DeAngelo D, Neuberg D, Stone R, Ball B, Stahl M. Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study. Blood 2023, 142: 1589. DOI: 10.1182/blood-2023-174283.
- Shimony S, Bewersdorf J, Shallis R, Liu Y, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Chen E, Ramos J, Lindsley R, Stein A, DeAngelo D, Neuberg D, Stone R, Ball B, Stahl M. What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study. Blood 2023, 142: 1478. DOI: 10.1182/blood-2023-172763.
- Bale S, Kim C, How J, Wazir M, Weeks L, Stahl M, Luskin M, DeAngelo D, Lindsley C, Kim A, Mullally A, Marneth A. Mutations in the RNA Splicing Factors U2AF1 and SRSF2 are Context-Dependent in Myeloproliferative Neoplasms. Blood 2023, 142: 1788. DOI: 10.1182/blood-2023-178657.
- Daver N, Stein A, Bixby D, Chai-Ho W, Zeidner J, Maher K, Stevens D, Stahl M, Yee K, Curran E, Ito S, Sochacki A, Sallman D, Hernandez R, Metenou S, Ma B, Kato K, Zeidan A. Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts). Blood 2023, 142: 4278. DOI: 10.1182/blood-2023-173991.
- No Increased Incidence of Bleeding in Essential Thrombocythemia Patients with Extreme ThrombocytosisVenkat R, Redd R, Aryee M, Marneth A, Kamaz B, Kim C, Wazir M, Weeks L, Stahl M, DeAngelo D, Lindsley C, Luskin M, Hobbs G, How J. No Increased Incidence of Bleeding in Essential Thrombocythemia Patients with Extreme Thrombocytosis. Blood 2023, 142: 1839. DOI: 10.1182/blood-2023-187530.
- Winer E, Garcia J, Stone R, Wadleigh M, Luskin M, Stahl M, Chen E, Leonard R, Noyes A, Galinsky I, Deshpande R, Borderies P, O'Neill V, DeAngelo D. Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 2023, 142: 1549. DOI: 10.1182/blood-2023-186598.
- Shimony S, Garcia J, Keating J, Chen E, Luskin M, Stahl M, Neuberg D, DeAngelo D, Stone R, Lindsley R. Molecular Ontogeny in AML Is Both Prognostic and Predictive in Patients Treated with Hypomethylating Agents Plus Venetoclax. Blood 2023, 142: 977. DOI: 10.1182/blood-2023-173935.
- Garcia-Manero G, Ooi M, Lao Z, Gill H, Abaza Y, Stahl M, Haque T, DeZern A, Greenberg P, Pelletier M, Singh A, Carreon D, Beaulieu V, Woo J. Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study. Blood 2023, 142: 3250. DOI: 10.1182/blood-2023-174642.
- Volpe V, Luskin M, Stahl M, Lindsley C, DeAngelo D. Common Pathways for Acute Myeloid Leukemia Progression in Systemic Mastocytosis with Associated Hematologic Neoplasm. Blood 2023, 142: 6400. DOI: 10.1182/blood-2023-184587.
- How J, Leiva O, Marneth A, Kamaz B, Kim C, Weeks L, Wazir M, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hobbs G. Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes. Blood 2023, 142: 4568. DOI: 10.1182/blood-2023-179324.
- Luskin M, Murakami M, Keating J, Winer E, Garcia J, Stahl M, Wadleigh M, Flamand Y, Neuberg D, Galinsky I, Leonard R, Hagopian E, Weizer C, McLanahan C, Stone R, Wang E, Stock W, DeAngelo D. A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults. Blood 2023, 142: 965. DOI: 10.1182/blood-2023-174246.
- Osei M, Merz L, Chien K, Hammond D, Lindsley C, Luskin M, Stahl M, How J, Wazir M, Marneth A, Shimony S, Mullally A, DeAngelo D, Garcia-Manero G, Achebe M, Ebert B, Weeks L. Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs). Blood 2023, 142: 2427. DOI: 10.1182/blood-2023-172992.
- Lane A, Garcia J, Raulston E, Garzon J, Galinsky I, Baxter E, Leonard R, DeAngelo D, Luskin M, Reilly C, Stahl M, Stone R, Vedula R, Wadleigh M, Winer E, Mughal T, Brooks C, Gupta I, Stevenson K, Neuberg D, Ren S, Konopleva M, Stein A, Pemmaraju N. Tagraxofusp in Combination with Azacitidine and Venetoclax in Newly Diagnosed CD123+ Acute Myeloid Leukemia, Expansion Cohort of a Phase 1b Multicenter Trial. Blood 2023, 142: 4277. DOI: 10.1182/blood-2023-180010.
- How J, Marneth A, Kamaz B, Kim C, Neuberg D, Ren S, Wazir M, Weeks L, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hormoz S, Mullally A. Unlike TET2 and ASXL1, Co-Occurring DNMT3A Mutations Are Not Associated with Increased Age in JAK2-Mutant Myeloproliferative Neoplasms (MPNs). Blood 2023, 142: 4521. DOI: 10.1182/blood-2023-179407.
- Bewersdorf J, Shimony S, Shallis R, Liu Y, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Lindsley R, Chen E, Ramos J, Stein A, DeAngelo D, Neuberg D, Stone R, Ball B, Stahl M. Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study. Blood 2023, 142: 2964. DOI: 10.1182/blood-2023-174285.
- Rolles B, De Oliveira Filho C, Keating J, Luskin M, DeAngelo D, Lindsley C, Kim A, Hem J, Kim C, Weeks L, Wazir M, How J, Marneth A, Liu Y, Aryee M, Tsai H, Stahl M, Mullally A. TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms. Blood 2023, 142: 3160. DOI: 10.1182/blood-2023-185024.
- Kewan T, Bewersdorf J, Gurnari C, Xie Z, Stahl M, Zeidan A. When to use which molecular prognostic scoring system in the management of patients with MDS? Best Practice & Research Clinical Haematology 2023, 36: 101517. PMID: 38092484, DOI: 10.1016/j.beha.2023.101517.
- Bewersdorf J, Stahl M, Taylor J, Mi X, Chandhok N, Watts J, Derkach A, Wysocki M, Lu S, Bourcier J, Hogg S, Rahman J, Chaudhry S, Totiger T, Abdel-Wahab O, Stein E. E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia 2023, 37: 2512-2516. PMID: 37814121, PMCID: PMC10681888, DOI: 10.1038/s41375-023-02050-4.
- Shimony S, Fell G, Chen E, Tsai H, Wadleigh M, Winer E, Garcia J, Luskin M, Stahl M, Neuberg D, DeAngelo D, Lindsley R, Stone R. FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients age ≥60 years. Blood Advances 2023, 7: 5354-5358. PMID: 37163357, PMCID: PMC10509660, DOI: 10.1182/bloodadvances.2023009748.
- Santinelli E, Pascale M, Xie Z, Badar T, Stahl M, Bewersdorf J, Gurnari C, Zeidan A. Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution. Blood Reviews 2023, 62: 101130. PMID: 37679263, DOI: 10.1016/j.blre.2023.101130.
- Stahl M, Bewersdorf J, Xie Z, Porta M, Komrokji R, Xu M, Abdel-Wahab O, Taylor J, Steensma D, Starczynowski D, Sekeres M, Sanz G, Sallman D, Roboz G, Platzbecker U, Patnaik M, Padron E, Odenike O, Nimer S, Nazha A, Majeti R, Loghavi S, Little R, List A, Kim T, Hourigan C, Hasserjian R, Halene S, Griffiths E, Gore S, Greenberg P, Figueroa M, Fenaux P, Efficace F, DeZern A, Daver N, Churpek J, Carraway H, Buckstein R, Brunner A, Boultwood J, Borate U, Bejar R, Bennett J, Wei A, Santini V, Savona M, Zeidan A. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews 2023, 62: 101128. PMID: 37704469, DOI: 10.1016/j.blre.2023.101128.
- Sherban A, Fredman D, Shimony S, Yeshurun M, Raanani P, Stahl M, Gafter-Gvili A, Wolach O. Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML – A systematic review. Leukemia Research 2023, 133: 107368. PMID: 37598660, DOI: 10.1016/j.leukres.2023.107368.
- Stahl M, Giblin G, Liu Y, Winer E, Garcia J, Chen E, Wadleigh M, Ling K, Lindsley R, Shimony S, Copson K, Charles A, DeAngelo D, Stone R, Nohria A, Luskin M. Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia. Leukemia Research 2023, 132: 107351. PMID: 37451200, DOI: 10.1016/j.leukres.2023.107351.
- Rotter L, Shimony S, Ling K, Chen E, Shallis R, Zeidan A, Stahl M. Epidemiology and Pathogenesis of Myelodysplastic Syndrome. The Cancer Journal 2023, 29: 111-121. PMID: 37195766, DOI: 10.1097/ppo.0000000000000665.
- Stempel J, Xie Z, Bewersdorf J, Stahl M, Zeidan A. Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms. The Cancer Journal 2023, 29: 203-211. PMID: 37195777, DOI: 10.1097/ppo.0000000000000666.
- Bewersdorf J, Xie Z, Bejar R, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, Porta M, DeZern A, Fenaux P, Figueroa M, Gore S, Griffiths E, Halene S, Hasserjian R, Hourigan C, Kim T, Komrokji R, Kuchroo V, List A, Loghavi S, Majeti R, Odenike O, Patnaik M, Platzbecker U, Roboz G, Sallman D, Santini V, Sanz G, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Xu M, Savona M, Wei A, Zeidan A. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Reviews 2023, 60: 101072. PMID: 36934059, DOI: 10.1016/j.blre.2023.101072.
- Badar T, Atallah E, Shallis R, Saliba A, Patel A, Bewersdorf J, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg A, Abaza Y, Murthy G, Kota V, Litzow M. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia 2023, 37: 799-806. PMID: 36807649, DOI: 10.1038/s41375-023-01847-7.
- Frumm S, Shimony S, Stone R, DeAngelo D, Bewersdorf J, Zeidan A, Stahl M. Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. Blood Reviews 2023, 60: 101056. PMID: 36805300, DOI: 10.1016/j.blre.2023.101056.
- Shimony S, Stahl M, Stone R. Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management. American Journal Of Hematology 2023, 98: 502-526. PMID: 36594187, DOI: 10.1002/ajh.26822.
- Badar T, Litzow M, Shallis R, Patel A, Saliba A, Burkart M, Bewersdorf J, Stahl M, De Camargo Correia G, Murthy S, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg A, Palmisiano N, Al Kali A, Atallah E. Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia. Cancer 2022, 129: 934-945. PMID: 36545710, DOI: 10.1002/cncr.34604.
- Przespolewski A, Goldberg A, Talati C, Fazal S, Vachhani P, Sanikommu S, Thota S, Waksal J, Ball B, Famulare C, Stahl M, Baron J, Griffiths E, Thompson J, Sweet K, Wang E. Safety and efficacy of CPX-351 in younger patients (< 60 years) with secondary acute myeloid leukemia. Blood 2022, 141: 1489-1493. PMID: 36493344, DOI: 10.1182/blood.2022016678.
- Bewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stein E, Huntington S, Zeidan A. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia. Leukemia & Lymphoma 2022, 64: 454-461. PMID: 36493798, PMCID: PMC9957935, DOI: 10.1080/10428194.2022.2140288.
- Shimony S, Fell G, Chen E, Tsai H, Wadleigh M, Winer E, Garcia J, Luskin M, Stahl M, Neuberg D, DeAngelo D, Lindsley R, Stone R. FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3-wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study. Blood 2022, 140: 8938-8939. DOI: 10.1182/blood-2022-162716.
- Sherban A, Fredman D, Shimony S, Yeshurun M, Raanani P, Stahl M, Gafter-Gvili A, Wolach O. Safety and Efficacy of FLAG-Ida Combined with Venetoclax Treatment for Newly Diagnosed and Relapsed / Refractory AML Patients- a Systematic Review. Blood 2022, 140: 11716-11717. DOI: 10.1182/blood-2022-163152.
- Badar T, Atallah E, Saliba A, Shallis R, Stahl M, Bewersdorf J, De Camargo Correia G, Patel A, Abaza Y, Murthy S, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kota V, Dinner S, Goldberg A, Litzow M. Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2022, 140: 6058-6060. DOI: 10.1182/blood-2022-163795.
- Badar T, Atallah E, Shallis R, Saliba A, Stahl M, Bewersdorf J, Grenet J, Patel A, Abaza Y, Murthy S, Duvall A, Burkart M, Palmisiano N, Kubiak M, Kota V, Dinner S, Goldberg A, Litzow M. Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2022, 140: 1435-1437. DOI: 10.1182/blood-2022-167731.
- Winer E, Flamand Y, Shallis R, Stempel J, Goldberg A, Stahl M, Patel A, Duvall A, Abaza Y, Oh T, Ma K, Badar T, Litzow M, Kota V, Bradshaw D, Raman H, Luskin M, Stone R, DeAngelo D. Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhigh but Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age. Blood 2022, 140: 6285-6287. DOI: 10.1182/blood-2022-170587.
- Bewersdorf J, Stahl M, Taylor J, Chandhok N, Watts J, Derkach A, Wysocki M, Kostantakis V, Lu S, Bourcier J, Hogg S, Totiger T, Abdel-Wahab O, Stein E. A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes. Blood 2022, 140: 9065-9067. DOI: 10.1182/blood-2022-156830.
- Bewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stempel J, Stein E, Huntington S, Zeidan A. Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid Leukemia. Blood 2022, 140: 319-321. DOI: 10.1182/blood-2022-158465.
- Bewersdorf J, Grimshaw A, Platzbecker U, Fenaux P, Sekeres M, Zeidan A, Stahl M. International Working Group (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents - a Systematic Review and Meta-Analysis. Blood 2022, 140: 9811-9812. DOI: 10.1182/blood-2022-158622.
- Marneth A, Jutzi J, Kim C, Laurore C, Tishena A, Kramer F, Rocha A, Wazir M, Weeks L, How J, Stahl M, Luskin M, Lindsley R, Pozdnyakova O, Graubert T, Mullally A. Mutant Srsf2 Diminishes Jak2V617F -Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2-Mutant MPN. Blood 2022, 140: 1089-1090. DOI: 10.1182/blood-2022-158823.
- Stahl M, Giblin G, Liu Y, DeAngelo D, Stone R, Winer E, Wadleigh M, Lindsley C, Shimony S, Copson K, Charles A, Nohria A, Luskin M. Genetic Predictors of Anthracycline Mediated Cardiomyopathy with Induction Chemotherapy in Acute Myeloid Leukemia (AML). Blood 2022, 140: 6067-6068. DOI: 10.1182/blood-2022-159193.
- Xie Z, Chen E, Stahl M, Zeidan A. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age. Blood Reviews 2022, 59: 101033. PMID: 36357283, DOI: 10.1016/j.blre.2022.101033.
- Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia 2022, 36: 2934-2938. PMID: 36335264, DOI: 10.1038/s41375-022-01754-3.
- Stahl M, Derkach A, Farnoud N, Bewersdorf J, Robinson T, Famulare C, Cho C, Devlin S, Menghrajani K, Patel M, Cai S, Miles L, Bowman R, Geyer M, Dunbar A, Epstein‐Peterson Z, McGovern E, Schulman J, Glass J, Taylor J, Viny A, Stein E, Getta B, Arcila M, Gao Q, Barker J, Shaffer B, Papadopoulos E, Gyurkocza B, Perales M, Abdel‐Wahab O, Levine R, Giralt S, Zhang Y, Xiao W, Pai N, Papaemmanuil E, Tallman M, Roshal M, Goldberg A. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. American Journal Of Hematology 2022, 98: 79-89. PMID: 36251406, PMCID: PMC10080561, DOI: 10.1002/ajh.26757.
- Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. Leukemia & Lymphoma 2022, 64: 188-196. PMID: 36287540, PMCID: PMC9905301, DOI: 10.1080/10428194.2022.2136952.
- Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 2022, 36: 2939-2946. PMID: 36266326, DOI: 10.1038/s41375-022-01724-9.
- Stahl M, Shallis R, Derkach A, Goldberg A, Stein A, Stein E, Marcucci G, Zeidan A, Shimony S, DeAngelo D, Stone R, Aldoss I, Ball B, Bewersdorf J. Poster: AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma & Leukemia 2022, 22: s128. DOI: 10.1016/s2152-2650(22)00761-3.
- Stahl M, Shallis R, Derkach A, Goldberg A, Stein A, Stein E, Marcucci G, Zeidan A, Shimony S, DeAngelo D, Stone R, Aldoss I, Ball B, Bewersdorf J. AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma & Leukemia 2022, 22: s209-s210. DOI: 10.1016/s2152-2650(22)01214-9.
- Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. Leukemia Research 2022, 122: 106942. PMID: 36108424, DOI: 10.1016/j.leukres.2022.106942.
- Shimony S, Rozental A, Bewersdorf J, Goldberg A, Stein E, Grimshaw A, Stone R, DeAngelo D, Wolach O, Stahl M. Investigational venetoclax combination therapy in acute myeloid leukemia – a systematic review and meta-analysis. Haematologica 2022, 107: 2955-2960. PMID: 36453519, PMCID: PMC9713559, DOI: 10.3324/haematol.2022.281453.
- Badar T, Litzow M, Shallis R, Stahl M, Bewersdorf J, Saliba A, de Camargo Correia G, Patel A, Abaza Y, Murthy S, Duvall A, Burkart M, Al-Kali A, Palmisiano N, Dinner S, Goldberg A, Atallah E. Racial disparities in patients with TP53 mutated acute myeloid leukemia. Journal Of Clinical Oncology 2022, 40: e19007-e19007. DOI: 10.1200/jco.2022.40.16_suppl.e19007.
- Shallis RM, Bewersdorf JP, Stahl MF, Halene S, Zeidan AM. Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia? Cancers 2022, 14: 2434. PMID: 35626039, PMCID: PMC9140008, DOI: 10.3390/cancers14102434.
- Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JM. Outcomes of TP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. American Journal Of Hematology 2022, 97: e232-e235. PMID: 35338673, DOI: 10.1002/ajh.26546.
- North K, Benbarche S, Liu B, Pangallo J, Chen S, Stahl M, Bewersdorf J, Stanley R, Erickson C, Cho H, Pineda J, Thomas J, Polaski J, Belleville A, Gabel A, Udy D, Humbert O, Kiem H, Abdel-Wahab O, Bradley R. Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. Nature Biotechnology 2022, 40: 1103-1113. PMID: 35241838, PMCID: PMC9288984, DOI: 10.1038/s41587-022-01224-2.
- Shimony S, Stone R, Stahl M. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. Current Opinion In Hematology 2021, 29: 63-73. PMID: 34966123, DOI: 10.1097/moh.0000000000000698.
- Shallis R, Stahl M, Bewersdorf J, Zeidan A. The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia. Hemato 2021, 2: 748-763. DOI: 10.3390/hemato2040051.
- Grenet J, Jain A, Burkart M, Waksal J, Famulare C, Numan Y, Stahl M, Mckinnell Z, Ball B, Ma X, Christos P, Ritchie E, Samuel M, Kaner J, Lee S, Goldberg A, Dinner S, Sweet K, Roboz G, Desai P. Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia. Blood 2021, 138: 32. DOI: 10.1182/blood-2021-145947.
- Desai P, Goldberg A, Anderson K, Narendra V, Neuberg D, Radhakrishnan V, Redd R, Roboz G, Sehn L, Sekeres M, Stahl M, Tallman M, Thompson J, Tucker E, Wood W, Hicks L. Clinical Predictors of Outcome in Adult Patients with Acute Leukemias and Myelodysplastic Syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub. Blood 2021, 138: 280. PMCID: PMC8701680, DOI: 10.1182/blood-2021-146016.
- Wang E, Pineda J, Bourcier J, Stahl M, Penson A, Wakiro I, Singer M, Cui D, Erickson C, Knorr K, Stanley R, Chen X, McMillan E, Bossard C, Aifantis I, Bradley R, Abdel-Wahab O. Modulation of RNA Splicing Enhances Response to BCL2 Inhibition in Acute Myeloid Leukemia. Blood 2021, 138: 507. DOI: 10.1182/blood-2021-146373.
- Badar T, Litzow M, Shallis R, Bewersdorf J, Saliba A, De Camargo Correia G, Stahl M, Goldberg A, Atallah E, Foran J. Multicenter Analysis of Treatment and Outcomes for Patient with TP53 Mutated AML in the Era of Novel Therapies; Significant Impact of Allogeneic Stem Cell Transplantation on Survival. Blood 2021, 138: 797. DOI: 10.1182/blood-2021-147639.
- Myers R, Izzo F, Prieto T, Mimitou E, Raviram R, Chaligne R, Hoffman R, Stahl M, Abdel-Wahab O, Marcellino B, Smibert P, Landau D. High Throughput Single-Cell Simultaneous Genotyping and Chromatin Accessibility Reveals Genotype to Phenotype Relationship in Human Myeloproliferation. Blood 2021, 138: 678. DOI: 10.1182/blood-2021-149226.
- Przespolewski A, Goldberg A, Talati C, Fazal S, Vachhani P, Sanikommu S, Thota S, Waksal J, Ball B, Famulare C, Stahl M, Mckinnell Z, Baron J, Griffiths E, Thompson J, Sweet K, Wang E. Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis. Blood 2021, 138: 1264. DOI: 10.1182/blood-2021-153791.
- Hicks L, Redd R, Anderson K, Desai P, Dolan B, Goldberg A, Narendra V, Neuberg D, Radhakrishnan V, Sehn L, Sekeres M, Stahl M, Tallman M, Thompson J, Tucker E, Wood W. Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology. Blood 2021, 138: 3040. PMCID: PMC8701544, DOI: 10.1182/blood-2021-154283.
- King A, Weis T, Derkach A, Ball S, Pandey M, Mauro M, Goldberg A, Stahl M, Famulare C, Tallman M, Wang E, Kuykendall A, Rampal R. Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. American Journal Of Hematology 2021, 97: e7-e10. PMID: 34674293, DOI: 10.1002/ajh.26381.
- Bewersdorf J, Stone R, Tallman M, Stahl M. Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML? Leukemia & Lymphoma 2021, 62: 3318-3319. PMID: 34587866, DOI: 10.1080/10428194.2021.1986220.
- Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 997.e1-997.e11. PMID: 34551341, PMCID: PMC9533376, DOI: 10.1016/j.jtct.2021.09.005.
- Bewersdorf J, Tallman M, Stahl M. Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept. Current Opinion In Oncology 2021, 33: 658-669. PMID: 34341323, DOI: 10.1097/cco.0000000000000778.
- Stahl M, Tallman M, Goldberg A. Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey. Leukemia & Lymphoma 2021, 62: 2050-2051. PMID: 34519611, DOI: 10.1080/10428194.2021.1929967.
- Stahl M, Narendra V, Jee J, Derkach A, Maloy M, Geyer M, Mato A, Roeker L, Tallman M, Shah G, Daniyan A, Goldberg A. Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leukemia & Lymphoma 2021, 62: 1940-1948. PMID: 34180767, PMCID: PMC10080398, DOI: 10.1080/10428194.2021.1885664.
- Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 873.e1-873.e13. PMID: 34052505, PMCID: PMC8478722, DOI: 10.1016/j.jtct.2021.05.016.
- Xiao W, Chan A, Waarts M, Mishra T, Liu Y, Cai S, Yao J, Gao Q, Bowman R, Koche R, Csete I, DelGaudio N, Derkach A, Baik J, Yanis S, Famulare C, Patel M, Arcila M, Stahl M, Rampal R, Tallman M, Zhang Y, Dogan A, Goldberg A, Roshal M, Levine R. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood 2021, 137: 1377-1391. PMID: 32871587, PMCID: PMC7955409, DOI: 10.1182/blood.2020007897.
- Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King A, Daniyan A, Famulare C, Cuello B, Horvat T, Abdel-Wahab O, Levine R, Viny A, Stein E, Cai S, Roshal M, Tallman M, Goldberg A. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances 2021, 5: 1552-1564. PMID: 33687434, PMCID: PMC7948282, DOI: 10.1182/bloodadvances.2020003734.
- Pollyea D, Stahl M, Talati C, Asghari H, Lai C, Abedin S, Zeidner J, Muluneh B, Xavier M, Edwards W, Wolach O, Moshe Y, Lavie D, Zuckerman T, Choi M, Bui C, Svensson A, Kye S, Burne R, Guerin A, Ma E, Montez M, Goldberg A. Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative. Blood 2020, 136: 26-28. DOI: 10.1182/blood-2020-134789.
- Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King A, Daniyan A, Famulare C, Cuello B, Abdel-Wahab O, Levine R, Viny A, Stein E, Roshal M, Tallman M, Goldberg A. Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors. Blood 2020, 136: 47-48. DOI: 10.1182/blood-2020-137815.
- Bewersdorf J, Tallman M, Cho C, Zeidan A, Stahl M. Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis. Blood 2020, 136: 34-35. DOI: 10.1182/blood-2020-136671.
- Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. International Journal Of Hematology 2020, 113: 92-99. PMID: 32951163, DOI: 10.1007/s12185-020-02994-8.
- Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis. Leukemia 2020, 35: 1643-1660. PMID: 32868875, PMCID: PMC7917159, DOI: 10.1038/s41375-020-01020-4.
- Stahl M, Epstein-Peterson Z, Intlekofer A. Oncogenic Mechanisms and Therapeutic Targeting of Metabolism in Leukemia and Lymphoma. Cold Spring Harbor Perspectives In Medicine 2020, 11: a035477. PMID: 32816875, PMCID: PMC8247556, DOI: 10.1101/cshperspect.a035477.
- Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, Stahl M. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta‐analysis. Transfusion 2020, 60: 2360-2369. PMID: 32776542, PMCID: PMC8631180, DOI: 10.1111/trf.15994.
- Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, Tallman MS, Zeidan AM, Stahl M. Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma & Leukemia 2020, 20: e712-e723. PMID: 32669244, PMCID: PMC7541411, DOI: 10.1016/j.clml.2020.05.018.
- Shallis RM, Stahl M, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Review Of Hematology 2020, 13: 489-499. PMID: 32248712, DOI: 10.1080/17474086.2020.1751609.
- Stahl M, Tallman M. Late and very late relapses in acute myeloid leukemia (AML). Leukemia & Lymphoma 2020, 61: 1010-1011. PMID: 32283963, DOI: 10.1080/10428194.2020.1745204.
- Pine AB, Chokr N, Stahl M, Steensma DP, Sekeres MA, Litzow MR, Luger SM, Stone RM, Greenberg PL, Bejar R, Bewersdorf JP, Gore SD, Zeidan AM. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leukemia & Lymphoma 2020, 61: 1455-1464. PMID: 32026740, DOI: 10.1080/10428194.2020.1723013.
- Stahl M, Tallman M. Outcomes of allogeneic stem cell transplantation for patients with t(6:9) AML‐ A strong case for allogeneic stem cell transplantation in first complete remission. British Journal Of Haematology 2020, 189: 806-808. PMID: 31999852, DOI: 10.1111/bjh.16478.
- Bewersdorf JP, Giri S, Wang R, Williams RT, Tallman MS, Zeidan AM, Stahl M. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica 2020, 105: 2659-2663. PMID: 33131256, PMCID: PMC7604631, DOI: 10.3324/haematol.2019.242826.
- Agrawal V, Gbolahan OB, Stahl M, Zeidan AM, Zaid MA, Farag SS, Konig H. Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia. Current Cancer Drug Targets 2020, 20: 473-489. PMID: 32357813, DOI: 10.2174/1568009620666200502011059.
- Stahl M, Tallman M. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leukemia & Lymphoma 2019, 60: 3107-3115. PMID: 31842650, PMCID: PMC7479633, DOI: 10.1080/10428194.2019.1613540.
- Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2019, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.
- Stahl M, Tallman M. Differentiation syndrome in acute promyelocytic leukaemia. British Journal Of Haematology 2019, 187: 157-162. PMID: 31410848, DOI: 10.1111/bjh.16151.
- Bewersdorf JP, Stahl M, Zeidan AM. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant. Expert Review Of Hematology 2019, 12: 575-578. PMID: 31225770, DOI: 10.1080/17474086.2019.1635005.
- Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leukemia & Lymphoma 2019, 60: 3181-3187. PMID: 31170846, DOI: 10.1080/10428194.2019.1622700.
- Stahl M, Tallman M. Antibody-based therapy in acute leukemia - beware the risks. Leukemia & Lymphoma 2019, 60: 1608-1609. PMID: 31204877, DOI: 10.1080/10428194.2019.1608535.
- Stahl M, Bewersdorf J, Giri S, Wang R, Zeidan AM. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica 2019, 105: 102-111. PMID: 31004015, PMCID: PMC6939518, DOI: 10.3324/haematol.2019.219345.
- Chokr N, Pine AB, Bewersdorf JP, Shallis RM, Stahl M, Zeidan AM. Getting personal with myelodysplastic syndromes: is now the right time? Expert Review Of Hematology 2019, 12: 215-224. PMID: 30977414, PMCID: PMC6540985, DOI: 10.1080/17474086.2019.1592673.
- Stahl M, Goldberg A. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets. Current Oncology Reports 2019, 21: 37. PMID: 30904967, DOI: 10.1007/s11912-019-0781-7.
- Zeidan A, Hu X, Zhu W, Stahl M, Giri S, Huntington S, Wang R, Podoltsev N, Gore S, Ma X, Davidoff A. Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis. Blood 2018, 132: 370. DOI: 10.1182/blood-2018-99-111052.
- Pine A, Chokr N, Stahl M, Steensma D, Sekeres M, Litzow M, Luger S, Stone R, Greenberg P, Bejar R, Gore S, Zeidan A. Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey. Blood 2018, 132: 1825. DOI: 10.1182/blood-2018-99-113888.
- Zeidan A, Zhu W, Wang R, Stahl M, Huntington S, Giri S, Podoltsev N, Gore S, Ma X, Davidoff A. Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions. Blood 2018, 132: 838. DOI: 10.1182/blood-2018-99-116497.
- Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review Of Hematology 2018, 11: 715-726. PMID: 30024293, DOI: 10.1080/17474086.2018.1503049.
- Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study. Journal Of Clinical Oncology 2017, 35: 7057-7057. DOI: 10.1200/jco.2017.35.15_suppl.7057.
- Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. 121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based Study. Leukemia Research 2017, 55: s75-s76. DOI: 10.1016/s0145-2126(17)30234-5.
- Stahl M, Zeidan AM. Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel? Cancer 2017, 123: 911-914. PMID: 28094843, DOI: 10.1002/cncr.30532.
- Stahl M, Kim TK, Zeidan AM. Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World Journal Of Stem Cells 2016, 8: 316-331. PMID: 27822339, PMCID: PMC5080639, DOI: 10.4252/wjsc.v8.i10.316.
- Stahl M, Kohrman N, Gore SD, Kim TK, Zeidan AM, Prebet T. Epigenetics in Cancer: A Hematological Perspective. PLOS Genetics 2016, 12: e1006193. PMID: 27723796, PMCID: PMC5065123, DOI: 10.1371/journal.pgen.1006193.
- Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Reviews 2016, 31: 43-62. PMID: 27745715, DOI: 10.1016/j.blre.2016.09.005.
- Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. Annals Of Hematology 2016, 95: 1895-1898. PMID: 27468851, PMCID: PMC10955604, DOI: 10.1007/s00277-016-2761-4.
- Stahl M, Gedrich R, Peck R, LaVallee T, Eder JP. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors. Immunotherapy 2016, 8: 767-774. PMID: 27349976, DOI: 10.2217/imt-2016-0040.
- Suozzi KC, Stahl M, Ko CJ, Chiang A, Gettinger SN, Siegel MD, Bunick CG. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Reports 2016, 2: 264-268. PMID: 27486590, PMCID: PMC4949498, DOI: 10.1016/j.jdcr.2016.05.002.
- Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Annals Of Hematology 2016, 95: 1197-1200. PMID: 27068405, PMCID: PMC7479634, DOI: 10.1007/s00277-016-2664-4.
- Stahl M, Mohareb AM, Lee AI, Federman DG, Siddon AJ, Spelman J. Multi‐system complications of hypereosinophilia. American Journal Of Hematology 2016, 91: 444-447. PMID: 26700720, DOI: 10.1002/ajh.24283.
- Stahl M, Gore SD, Vey N, Prebet T. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Expert Opinion On Investigational Drugs 2016, 25: 307-317. PMID: 26807602, DOI: 10.1517/13543784.2016.1146251.
- Stahl K, Stahl M, de Jonge HR, Forrest JN. ANP and CNP activate CFTR expressed in Xenopus laevis oocytes by direct activation of PKA. Journal Of Receptors And Signal Transduction 2015, 35: 493-504. PMID: 26016495, DOI: 10.3109/10799893.2015.1015738.
- Stahl M, Stahl K, Brubacher MB, Forrest JN. Divergent CFTR orthologs respond differently to the channel inhibitors CFTRinh-172, glibenclamide, and GlyH-101. American Journal Of Physiology - Cell Physiology 2011, 302: c67-c76. PMID: 21940661, PMCID: PMC3328903, DOI: 10.1152/ajpcell.00225.2011.
- Blood 2016 128:1063;The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort
Locations
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl NP7
New Haven, CT 06511
- Smilow Cancer Hospital at Yale New Haven35 Park Street, Fl NP7New Haven, CT 06511
Smilow Cancer Hospital at Yale New Haven
35 Park Street, Fl NP7
New Haven, CT 06511
- Smilow Cancer Hospital at Yale New Haven35 Park Street, Fl NP7New Haven, CT 06511